• Follow
  • Follow
  • Follow
  • Follow
U

Search



Shop

w

News

w

Blog

DONATE
Team Jack Foundation
  • About Us
    • Our Mission
    • Jack Hoffman
    • Board & Staff
    • Financials
  • Our Impact
    • Scientific Advisory Board
    • Sponsored Grants
    • Research Articles
  • Brain Cancer
    • What is Brain Cancer?
      • What is DIPG?
    • Brain Cancer Facts
    • Cancer Awareness Months
      • Brain Tumor Awareness Month
    • Family Resources
  • Events
  • Get Involved
    • Fundraise
      • Host an Event
      • Run For Team Jack
      • Birthday Fundraiser
    • Give
    • Our Sponsors
    • Volunteer
  • Heroes
  • Donate
  • Shop
  • Blog
  • News
Select Page

Get Involved

Clinical Trial Finder

Search Results

Evaluation of a Novel CT-On-Rails or Trilogy Stereotactic Spine Radiotherapy System (SSRS)

Study Purpose

The goal of this clinical research study is to find out if stereotactic spine radiotherapy is safe and effective in the treatment of metastatic spine tumors. The feasibility of this type of treatment will be studied as will any side effects related to the treatment. The precision and accuracy of the CT-on-rails will also be studied.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages N/A and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

1. Radiographically documented spine or paraspinal metastasis demonstrated on spine MRI within 4 wks of registration. 2. Maximum of 2 metastatic sites in the spine to be irradiated over a single course of treatment. 3. Informed consent for irradiation or re-irradiation of spinal or para-spinal tumor (s) 4. Diagnosis cancer including but not limited to lung (non-small cell and small cell), breast, prostate, renal cell, melanoma, gastrointestinal, germ cell tumors, and unknown primary tumors. 5. Karnofsky performance status of at least 40 (i.e. not requiring active hospitalization) 6. Maximum of 1 prior course of spine radiotherapy to the current region of interest allowed.

Exclusion Criteria:

1. Worsening neurological status due to radiographic evidence of spinal cord compression requiring immediate surgical decompression or emergent conventional external radiation therapy. 2. Delay in initiation of radiation treatment would be potentially detrimental to neurological outcome. 3. Patients already re-treated with radiation as part of this protocol will not be eligible for additional re-treatment. 4. Unstable spine requiring surgical stabilization. 5. Sites outside the spine (eg. lung, liver) are not eligible for treatment. 6. Systemic radiotherapy (Sr-89) within 30 days. 7. Prior irradiation of the area to be treated within 3 months of registration. 8. Patients currently receiving, or who have received chemotherapy within 30 days are not eligible. 9. Inability to tolerate lying flat on treatment couch for greater than 30 minutes. 10. Patient with multiple myeloma. 11. Patients unable to undergo MRI of the spine. 12. Patients with pacemakers. 13. Patients who have previously received maximum cord tolerance of 45 Gy in 5 weeks conventional fractionation or equivalent dose to the current area to be treated.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT00508443
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 1/Phase 2
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

M.D. Anderson Cancer Center
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Amol J. Ghia, MD
Principal Investigator Affiliation M.D. Anderson Cancer Center
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Other
Overall Status Active, not recruiting
Countries United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Spinal Neoplasms
Study Website: View Trial Website
Additional Details

CT-On-Rails or Trilogy is a system that places the radiation treatment machine in the same room as the CT scanner so that the CT scanner can help deliver radiation more precisely. You will have a MRI of the spine within 1 month of registration on this study. You will also fill out a health survey (5 minutes), a symptom inventory ( 5 minutes), and a Brief Pain Inventory (5 minutes) within 1 week of registration. A pretreatment feasibility study will first be performed to determine the precision, accuracy, and reproducibility with which the target volume and critical normal structures (e.g. spinal cord) can be positioned relative to the radiation beams for spine tumors; this will consist of a CT scan. Patients will have a CT-simulation. The simulation is like a CT scan where a special body frame is used to keep the patient from moving during scanning and later treatment. You will be asked questions about your medical history and have a complete neurological exam during your first consultation. The neurological exam involves testing upper and lower motor strength, sensation to light touch, reflexes, mental exam, and way you walk. MRI of the spine must be performed within 1 month of registration. You will be asked to complete 3 questionnaires to evaluate your symptoms and pain. Each questionnaire will take around 5 minutes to complete, and should be completed within 1 month of being enrolled in the study. All patients will be treated with radiation therapy that is guided by the CT-on-Rails or Trilogy procedure. Patients will receive a CT scan immediately before the treatment in the same room of the treatment using CT-On-Rails or Trilogy. There will be a total of 3 treatments over a period of 2 weeks. Monitoring of side effects will be focused on neurological, gastrointestinal, musculoskeletal, and hematological systems. Every attempt will be made to have the patient complete the prescribed course of radiation to maximize the beneficial effect of treatment. However, if there is severe side effects, radiation treatment will be stopped and patients will be taken off study. You will have follow up visits once a week during radiation treatment, scheduled on the same day as radiation. After treatment, you will have telephone, mail, or follow-ups per fax scheduled at 2 and 4 weeks,and 2 months post radiation. You will have follow up visits scheduled at 3, 6, 9, 12, 18, and 24 months, then every six months for the rest of your life. At all follow-up visits, you will be asked questions about your medical history, have a neurological exam, and neurologic function will be evaluated. Any pain medication you are taking will be noted. You will have an MRI of the spine at 3, 6, 9, 12,18, and 24 months, then once a year for the rest of your life. You will also be asked to complete 3 questionnaires to evaluate your symptoms and pain. Each questionnaire will take around 5 minutes to complete. This is an investigational study. The CT-on-rails and Trilogy linear accelerator are FDA-approved medical devices and are commercially available, however, the way these two devices are being used is investigational. Up to 150 patients will take part in this study. All will be enrolled at M. D. Anderson.

Arms & Interventions

Arms

Experimental: Radiation Therapy

Radiation Therapy using CT-on-Rails or Trilogy procedure. Participants prescribed to receive 9 Gy x 3 so that a peripheral dose of 27 Gy is given to the tumor.

Interventions

Radiation: - Radiation Therapy

Three radiation treatments guided by the CT-on-Rails or Trilogy procedure over a period of 2 weeks. Participants prescribed to receive 9 Gy x 3 so that a peripheral dose of 27 Gy is given to the tumor.

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Houston 4699066, Texas 4736286

Status

Address

University of Texas MD Anderson Cancer Center

Houston 4699066, Texas 4736286, 77030

Nearest Location


Resources

  • Patient and Caregiver Survey
  • Clinical Trial Endpoints
  • Research Resources
Powered By

The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation.

Make an impact through your inbox

News, upcoming events and research updates delivered straight to your inbox.

  • This field is for validation purposes and should be left unchanged.
MAKE AN IMPACT

Donate today to help the Team Jack Foundation fund research and fight pediatric brain cancer.

Make a Donation
  • About Us
  • Our Mission
  • Jack Hoffman
  • Board & Staff
  • Fund Allocation
  • Financials
  • Our Impact
  • Scientific Advisory Board
  • Sponsored Grants
  • Research Articles
  • Brain Cancer
  • Family Resources
  • Get Involved
  • Fundraise
  • Give
  • Events
  • Our Sponsors
  • Volunteer
  • Follow
  • Follow
  • Follow
  • Follow
  • Follow
seal of transparency badge - 2019 Gold
combined health agencies drive member charity badge
Share Omaha member badge
© 2021 Team Jack Foundation. PO Box 607, Atkinson, NE, 68713. All Rights Reserved. Team Jack Foundation, Inc. is exempt from federal income tax under section 501(c)3, ID Number 46-2301134, of the internal revenue code. All contributions to the Foundation are tax deductible. Privacy Policy • Contact